baleraciclideg   Click here for help

GtoPdb Ligand ID: 14627

Synonyms: compound PPA-044 [WO2022263604] | CT-7439 | CT7439
Compound class: Synthetic organic
Comment: Baleraciclideg is the INN for a cyclin-dependent kinase degrader that was included in WHO INN Proposed List 135 (July 2026). The structure is claimed in Carrick Therapeutics' patent WO2022263604A1, as a CDK12/13 inhibitor and cyclin K molecular glue class degrader [1]. The inhibitor is proposed to simultaneously occupy kinase domain of CDK12 and engage the hydrophobic pocket of the DDB1 E3 ligase to promote cyclin K degradation. Carrick Therapeutics have a declared lead compound called CT7439 with this functionality in their development pipeline [2]. CT7439 is an orally bioavailable compound.

Targeting various CDKs is an established anti-tumour strategy.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 76.41
Molecular weight 439.56
XLogP 1.96
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=NC=C1)C2=CC=C(C=C2)CNC3=CC(=NC4=C(C=NN34)C5CC5)N[C@H]6CCCNC6
Isomeric SMILES C1C[C@@H](CNC1)NC2=NC3=C(C=NN3C(=C2)NCC4=CC=C(C=C4)C5=CC=CC=N5)C6CC6
InChI InChI=1S/C26H29N7/c1-2-13-28-23(5-1)20-8-6-18(7-9-20)15-29-25-14-24(31-21-4-3-12-27-16-21)32-26-22(19-10-11-19)17-30-33(25)26/h1-2,5-9,13-14,17,19,21,27,29H,3-4,10-12,15-16H2,(H,31,32)/t21-/m0/s1
InChI Key MGIDXACENIIRIH-NRFANRHFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
CT7439 was progressed as an anti-tumour candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06600789 A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies Phase 1/Phase 2 Interventional Carrick Therapeutics Limited